Biotechs may face a slowdown

January 12, 2015 | These are boom times in biotechnology. Forty-one new drugs were approved for US sale in 2014, the highest tally in 18 years. A record 63 biotech startups went public, breaking the 1999 record of 52 initial public offerings. And the value of biopharma merger deals nearly tripled to $223 billion from a year earlier. BostonGlobe.com